CY2021016I2 - Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv - Google Patents

Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv

Info

Publication number
CY2021016I2
CY2021016I2 CY2021016C CY2021016C CY2021016I2 CY 2021016 I2 CY2021016 I2 CY 2021016I2 CY 2021016 C CY2021016 C CY 2021016C CY 2021016 C CY2021016 C CY 2021016C CY 2021016 I2 CY2021016 I2 CY 2021016I2
Authority
CY
Cyprus
Prior art keywords
inhibitor activity
polycyclic carbamoylpyridone
hiv integration
carbamoylpyridone derivative
integration inhibitor
Prior art date
Application number
CY2021016C
Other languages
English (en)
Other versions
CY2021016I1 (el
Original Assignee
Viiv Healthcare Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2021016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Company filed Critical Viiv Healthcare Company
Publication of CY2021016I1 publication Critical patent/CY2021016I1/el
Publication of CY2021016I2 publication Critical patent/CY2021016I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY2021016C 2005-04-28 2021-05-26 Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv CY2021016I2 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
EP06758843.4A EP1874117B8 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
EP12159082.2A EP2465580B1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity

Publications (2)

Publication Number Publication Date
CY2021016I1 CY2021016I1 (el) 2021-10-15
CY2021016I2 true CY2021016I2 (el) 2021-12-31

Family

ID=37215098

Family Applications (7)

Application Number Title Priority Date Filing Date
CY20131101061T CY1115151T1 (el) 2005-04-28 2013-11-27 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] του hiv
CY20141100201T CY1116331T1 (el) 2005-04-28 2014-03-13 Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
CY2014024C CY2014024I2 (el) 2005-04-28 2014-06-25 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)κρασης [ενσωματασης] του hiv
CY20181100633T CY1120345T1 (el) 2005-04-28 2018-06-19 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης[ενσωματασης] toy hiv
CY20191100891T CY1122052T1 (el) 2005-04-28 2019-08-20 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv
CY2021016C CY2021016I2 (el) 2005-04-28 2021-05-26 Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
CY20211100866T CY1124601T1 (el) 2005-04-28 2021-10-06 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CY20131101061T CY1115151T1 (el) 2005-04-28 2013-11-27 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] του hiv
CY20141100201T CY1116331T1 (el) 2005-04-28 2014-03-13 Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
CY2014024C CY2014024I2 (el) 2005-04-28 2014-06-25 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)κρασης [ενσωματασης] του hiv
CY20181100633T CY1120345T1 (el) 2005-04-28 2018-06-19 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης[ενσωματασης] toy hiv
CY20191100891T CY1122052T1 (el) 2005-04-28 2019-08-20 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100866T CY1124601T1 (el) 2005-04-28 2021-10-06 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv

Country Status (29)

Country Link
US (22) US8129385B2 (el)
EP (9) EP3284519A1 (el)
JP (2) JP4295353B2 (el)
KR (4) KR101363875B1 (el)
AU (1) AU2006239177B8 (el)
BR (1) BRPI0610030B8 (el)
CA (1) CA2606282C (el)
CY (7) CY1115151T1 (el)
DK (6) DK3045206T3 (el)
EA (1) EA014162B1 (el)
ES (7) ES2567197T3 (el)
FI (1) FIC20210017I1 (el)
FR (1) FR14C0041I2 (el)
HK (2) HK1249742A1 (el)
HU (6) HUE056603T2 (el)
IL (4) IL186555A (el)
LT (5) LT3372281T (el)
LU (2) LU92446I2 (el)
MA (1) MA29460B1 (el)
MX (2) MX302718B (el)
NL (2) NL300676I2 (el)
NO (5) NO339525B1 (el)
NZ (1) NZ562339A (el)
PL (5) PL2465580T3 (el)
PT (5) PT1874117E (el)
SI (6) SI3045206T1 (el)
TW (1) TWI378931B (el)
VN (1) VN34404A1 (el)
WO (1) WO2006116764A1 (el)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496920T1 (de) 2003-12-24 2011-02-15 Biota Scient Management Polycyclische mittel zur behandlung von infektionen mit dem respiratory syncytial virus
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
EP3284519A1 (en) 2005-04-28 2018-02-21 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
EP1881825B1 (en) 2005-05-10 2013-07-24 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
ATE517899T1 (de) 2005-10-04 2011-08-15 Angeletti P Ist Richerche Bio Hiv-integrasehemmer
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
EP2574610A1 (en) * 2007-11-15 2013-04-03 Gilead Sciences, Inc. Inhibitors of human immonodeficiency virus replication
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
SG185995A1 (en) 2007-11-16 2012-12-28 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2465858B1 (en) 2008-07-25 2013-12-25 VIIV Healthcare Company Process for preparing a pyrido[1,2-a]pyrrolo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamide derivative
KR101772610B1 (ko) * 2008-07-25 2017-09-12 비이브 헬쓰케어 컴퍼니 화합물
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
HRP20140223T2 (hr) * 2008-07-25 2014-08-01 Viiv Healthcare Company Prolijekovi dolutegravir
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
CN104788367A (zh) 2008-12-11 2015-07-22 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
ES2641765T3 (es) * 2008-12-11 2017-11-13 Shionogi & Co., Ltd. Síntesis de inhibidores de integrasa de VIH carbamoilpiridona y productos intermedios
CN102239155A (zh) * 2008-12-11 2011-11-09 盐野义制药株式会社 生产麦芽糖醇醚的方法和中间体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
PL2444400T3 (pl) 2009-06-15 2018-08-31 Shionogi & Co., Ltd. Podstawiona policykliczna pochodna karbamoilopirydonowa
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
JP5624148B2 (ja) 2009-10-13 2014-11-12 エランコ・アニマル・ヘルス・アイルランド・リミテッド 大環状インテグラーゼ阻害剤
ME03058B (me) 2010-01-27 2019-01-20 Viiv Healthcare Co Antivirusna terapija
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
AU2014202406C1 (en) * 2010-01-27 2019-03-07 Viiv Healthcare Company Antiviral therapy
TWI508968B (zh) * 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
MX2012009869A (es) 2010-02-26 2012-09-12 Japan Tobacco Inc Derivado de 1, 3,4, 8-tetrahidro-2h-pirido[1, 2-a]pirazina y sus uso como inhibidor de la integrasa del vih.
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
JP5739517B2 (ja) 2010-04-02 2015-06-24 ヤンセン・アールアンドデイ・アイルランド 大環状インテグラーゼ阻害剤
JP5766690B2 (ja) * 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
DK3456721T3 (da) * 2010-08-05 2021-04-26 Shionogi & Co Fremgangsmåde til at fremstille forbindelser som har hiv-integrase-inhiberende aktivitet.
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
EP2620436B1 (en) * 2010-09-24 2018-05-09 Shionogi&Co., Ltd. Substituted polycyclic carbamoyl pyridone derivative prodrug
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
PL2742051T3 (pl) 2011-09-14 2017-06-30 Mapi Pharma Limited Amorficzna postać soli sodowej dolutegrawiru
KR20140090197A (ko) 2011-10-12 2014-07-16 시오노기세야쿠 가부시키가이샤 인터그라아제 억제 활성을 갖는 폴리사이클릭 피리돈 유도체
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
SI2797416T1 (sl) 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Substituirane spojine benzaldehida in metode njihove uporabe pri povečanju oksigenacije tkiva
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
BR122015029881B1 (pt) * 2012-12-21 2022-04-26 Gilead Sciences, Inc Compostos carbamoilpiridona policíclicos, composição farmacêutica que os compreende e seu uso farmacêutico
AU2013366981A1 (en) * 2012-12-27 2015-06-18 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor
US9480655B2 (en) 2013-02-18 2016-11-01 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014128545A2 (en) 2013-02-19 2014-08-28 Aurobindo Pharma Limited An improved process for the preparation of dolutegravir
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
AU2014237340C1 (en) 2013-03-15 2018-11-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN111454200A (zh) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
EP3016935B1 (en) * 2013-07-04 2018-09-05 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
NO2865735T3 (el) 2013-07-12 2018-07-21
SI3019503T1 (sl) * 2013-07-12 2017-11-30 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje HIV infekcij
EP3022209B1 (en) 2013-07-17 2018-03-07 ratiopharm GmbH Dolutegravir potassium salt
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
TN2016000090A1 (en) 2013-09-27 2017-07-05 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors.
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015108945A2 (en) 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015110897A2 (en) * 2014-01-21 2015-07-30 Laurus Labs Private Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
RS61653B2 (sr) 2014-02-07 2024-10-31 Global Blood Therapeutics Inc Kristalni polimorfni oblik slobodne baze 2-hidroksi-6-((2-(1-izopropil-1h-pirazol-5-il)piridin-3-il)metoksi)benzaldehid
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
CN106831819B (zh) * 2014-03-19 2019-01-04 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
NO2717902T3 (el) 2014-06-20 2018-06-23
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
EP3757105B1 (en) 2014-08-22 2024-07-24 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
EP3203995A4 (en) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
EP3253767A2 (en) 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Processes for the preparation of dolute-gravir
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
US10081647B2 (en) * 2015-03-26 2018-09-25 Merck Sharp & Dohme Corp. Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
EP3277691B1 (en) * 2015-04-02 2019-01-30 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
BR112017022550B1 (pt) * 2015-04-28 2021-02-23 Shionogi & Co., Ltd derivados policíclicos de piridona substituída
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
US10597404B2 (en) 2015-08-19 2020-03-24 Laurus Labs Ltd. Polymorphs of dolutegravir and salts thereof
EA201890654A1 (ru) 2015-11-09 2018-10-31 Джилид Сайэнс, Инк. Терапевтические композиции для лечения вируса иммунодефицита человека
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
BR112018011272A2 (pt) 2015-12-04 2018-11-21 Global Blood Therapeutics Inc regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído
EP3389380B1 (en) 2015-12-15 2021-07-21 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
PT3394069T (pt) 2015-12-21 2019-08-30 Lupin Ltd Processo para a preparação de inibidores de integrase de vih
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
JP7160466B2 (ja) * 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
CA3033667A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018057408A1 (en) * 2016-09-21 2018-03-29 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
AU2017367714B2 (en) 2016-12-02 2020-11-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
EP3363802B1 (en) * 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
CN110582504A (zh) * 2017-02-16 2019-12-17 桑多斯股份公司 卡博特韦钠的晶形
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
US11564921B2 (en) 2017-07-21 2023-01-31 Viiv Healthcare Company Regimens for treating HIV infections and AIDS
US20210040116A1 (en) 2017-09-07 2021-02-11 Cipla Limited New Polymorphs of Dolutegravir Sodium
AR113748A1 (es) 2017-10-06 2020-06-10 Shionogi & Co Proceso estereoselectivo para preparar derivados de piridona policíclicos sustituidos
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
WO2019199756A1 (en) 2018-04-09 2019-10-17 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
TWI880167B (zh) * 2018-05-31 2025-04-11 日商鹽野義製藥股份有限公司 多環性吡啶并三衍生物
KR102770090B1 (ko) * 2018-05-31 2025-02-18 시오노기 앤드 컴파니, 리미티드 다환성 피리돈 유도체
PL3805220T3 (pl) 2018-05-31 2024-11-04 Shionogi & Co., Ltd Policykliczne pochodne karbamoilopirydonu w leczeniu hiv
ES2975333T3 (es) 2018-07-12 2024-07-04 Laurus Labs Ltd Un proceso para la purificación de derivados policíclicos de carbamoilpiridona protegidos
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
WO2020086555A1 (en) 2018-10-22 2020-04-30 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
US20220175936A1 (en) 2018-11-29 2022-06-09 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
CA3128961A1 (en) 2019-03-22 2020-10-01 Hang CHU Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
AU2020402659A1 (en) 2019-12-09 2022-06-02 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
IL295677A (en) 2020-02-24 2022-10-01 Gilead Sciences Inc Tetracyclic compounds for treating hiv infection
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US20230321089A1 (en) 2020-09-01 2023-10-12 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
EP4222152A1 (en) 2020-09-30 2023-08-09 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
EP4255472A2 (en) 2020-12-07 2023-10-11 VIIV Healthcare Company Combination therapy
TW202408533A (zh) 2021-01-19 2024-03-01 美商基利科學股份有限公司 經取代之吡啶并三𠯤化合物及其用途
CN117715908A (zh) 2021-06-03 2024-03-15 江苏恒瑞医药股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其药用用途
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
US20250034607A1 (en) 2021-12-03 2025-01-30 Viiv Healthcare Company Process of Synthesizing (R)-3-aminobutan-1-ol
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
AU2024209826A1 (en) * 2023-01-18 2025-07-10 Ascletis BioScience Co., Ltd Integrase inhibitor and use thereof
WO2025068912A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja) * 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
DE69831506T2 (de) 1997-12-22 2006-06-29 Pharmacia & Upjohn Co. Llc, Kalamazoo 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
EP1297834A4 (en) † 2000-06-14 2007-05-09 Shionogi & Co ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
EP1326611B1 (en) 2000-10-12 2007-06-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
DE15187654T1 (de) 2001-08-10 2016-12-01 Shionogi & Co., Ltd Antivirales Mittel
CN102219750B (zh) 2001-10-26 2013-05-29 P.安杰莱蒂分子生物学研究所 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
SI1441734T1 (sl) 2001-10-26 2007-08-31 Angeletti P Ist Richerche Bio Dihidropirimidin karboksamidni inhibitorji HIV-integraze
US7279487B2 (en) 2002-01-17 2007-10-09 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
AU2003248872A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
AU2003257822A1 (en) 2002-08-13 2004-04-30 Shionogi And Co., Ltd. Heterocyclic compound having hiv integrase inhibitory activity
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
WO2004058756A1 (en) 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
EP1622615A4 (en) 2003-05-13 2009-02-18 Smithkline Beecham Corp INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
WO2005015927A1 (en) * 2003-08-12 2005-02-17 Rachel Beijer Scheduled message service
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
CA2555176A1 (en) 2004-02-11 2005-08-25 Smithkline Beecham Corporation Hiv integrase inhibitors
AU2005221864A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
CA2557785A1 (en) 2004-03-09 2005-10-06 Merck & Co. Inc. Hiv integrase inhibitors
EP1756114B1 (en) 2004-05-07 2014-11-19 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
CA2634499A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
US7858788B2 (en) * 2005-02-21 2010-12-28 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
US7981879B2 (en) * 2005-03-31 2011-07-19 Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. HIV integrase inhibitors
EP3284519A1 (en) * 2005-04-28 2018-02-21 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
JP2009503081A (ja) 2005-08-04 2009-01-29 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害薬
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica

Also Published As

Publication number Publication date
LUC00210I2 (el) 2022-10-07
KR101363875B1 (ko) 2014-02-21
EP2465580A1 (en) 2012-06-20
US20160207939A1 (en) 2016-07-21
ES2892304T3 (es) 2022-02-03
EP3045206B2 (en) 2023-02-15
ES2567197T3 (es) 2016-04-20
US20190284208A1 (en) 2019-09-19
HK1249742A1 (en) 2018-11-09
BRPI0610030B8 (pt) 2022-01-11
ES2667868T3 (es) 2018-05-14
IL225207A (en) 2017-11-30
CY1124601T1 (el) 2022-07-22
JP2009079058A (ja) 2009-04-16
US20190152990A1 (en) 2019-05-23
AU2006239177A1 (en) 2006-11-02
EP1874117B8 (en) 2014-03-12
KR20140097438A (ko) 2014-08-06
KR20080009733A (ko) 2008-01-29
DK3372281T3 (da) 2021-09-27
HUE037795T2 (hu) 2018-09-28
TWI378931B (en) 2012-12-11
US20220213121A1 (en) 2022-07-07
US20240279238A1 (en) 2024-08-22
JP4295353B2 (ja) 2009-07-15
MX312216B (en) 2013-08-12
ES2437268T3 (es) 2014-01-09
DK2465580T3 (en) 2014-03-10
EP3045206B1 (en) 2018-03-28
US8778943B2 (en) 2014-07-15
EA200702080A1 (ru) 2008-04-28
LT3045206T (lt) 2018-06-11
NL301109I1 (nl) 2021-09-15
HK1107227A1 (en) 2008-04-03
IL186555A0 (en) 2008-01-20
EP3284520A1 (en) 2018-02-21
HUS2100022I1 (hu) 2021-07-28
VN34404A1 (en) 2013-07-25
US20170209454A1 (en) 2017-07-27
CY1120345T1 (el) 2019-07-10
TW200716635A (en) 2007-05-01
CY1122052T1 (el) 2020-10-14
NO339525B1 (no) 2016-12-27
DK3187225T3 (da) 2022-02-28
EP1874117A4 (en) 2009-12-30
PL3045206T3 (pl) 2018-08-31
US11267823B2 (en) 2022-03-08
KR101580310B1 (ko) 2016-01-04
EP3372281A1 (en) 2018-09-12
PT3372281T (pt) 2021-10-14
US20120115875A1 (en) 2012-05-10
US20160304535A1 (en) 2016-10-20
CY1116331T1 (el) 2017-02-08
LT3284520T (lt) 2019-09-25
NO2017010I1 (no) 2017-03-27
KR101504998B1 (ko) 2015-03-23
EP3284519A8 (en) 2018-04-18
US9273065B2 (en) 2016-03-01
US20090318421A1 (en) 2009-12-24
ES2446324T3 (es) 2014-03-07
US20170029438A1 (en) 2017-02-02
FIC20210017I1 (fi) 2021-06-10
FR14C0041I1 (el) 2014-06-27
MX302718B (es) 2012-08-27
HUE056603T2 (hu) 2022-02-28
US20130172559A1 (en) 2013-07-04
EP3187226A1 (en) 2017-07-05
JP2008540343A (ja) 2008-11-20
LT3372281T (lt) 2021-12-10
EP3187225A1 (en) 2017-07-05
EP2527007A1 (en) 2012-11-28
US8129385B2 (en) 2012-03-06
HUE044978T2 (hu) 2019-11-28
AU2006239177B2 (en) 2011-10-20
BRPI0610030B1 (pt) 2020-09-15
AU2006239177B8 (en) 2012-02-16
EP3187225B1 (en) 2022-01-05
SI3372281T1 (sl) 2021-11-30
EP3284519A1 (en) 2018-02-21
FR14C0041I2 (fr) 2015-11-13
US20170224695A1 (en) 2017-08-10
PL3372281T3 (pl) 2021-12-27
ES2743531T3 (es) 2020-02-19
NO20161315A1 (no) 2007-11-22
US20140200209A1 (en) 2014-07-17
EA014162B1 (ru) 2010-10-29
SI3187225T1 (sl) 2022-04-29
DK1874117T3 (da) 2013-09-23
ES2667868T5 (es) 2023-06-01
EP1874117A1 (en) 2008-01-09
US20200339598A1 (en) 2020-10-29
PL3284520T3 (pl) 2020-01-31
NL300676I2 (el) 2016-10-11
IL186555A (en) 2016-10-31
US8410103B2 (en) 2013-04-02
SI3045206T1 (en) 2018-07-31
CA2606282C (en) 2016-04-26
CA2606282A1 (en) 2006-11-02
LTC1874117I2 (lt) 2025-03-25
PL2465580T3 (pl) 2014-05-30
CY2021016I1 (el) 2021-10-15
CY2014024I2 (el) 2025-05-09
BRPI0610030A2 (pt) 2011-10-11
EP3045206A1 (en) 2016-07-20
CY2014024I1 (el) 2015-12-09
MA29460B1 (fr) 2008-05-02
NO20075165L (no) 2007-11-22
KR101848819B1 (ko) 2018-04-16
PL1874117T3 (pl) 2014-01-31
PT2465580E (pt) 2014-02-25
CY1115151T1 (el) 2015-12-09
PT1874117E (pt) 2013-10-17
SI3284520T1 (sl) 2019-10-30
EP3284520B1 (en) 2019-06-05
NZ562339A (en) 2011-01-28
HK1172282A1 (en) 2013-04-19
PT3045206T (pt) 2018-07-05
KR20160003889A (ko) 2016-01-11
NO340111B1 (no) 2017-03-13
DK3045206T3 (en) 2018-05-22
US20170253616A1 (en) 2017-09-07
US20170145033A1 (en) 2017-05-25
EP2465580B1 (en) 2013-12-18
NO2021018I1 (no) 2021-05-10
EP1874117B1 (en) 2013-08-28
KR20130133061A (ko) 2013-12-05
US20160137666A1 (en) 2016-05-19
LTPA2014021I1 (lt) 2014-07-25
LTC2465580I2 (el) 2022-10-10
HK1251191A1 (en) 2019-01-25
HUS2100023I1 (hu) 2021-07-28
NO2023042I1 (no) 2023-11-08
NO2017010I2 (no) 2017-03-27
ES2906792T3 (es) 2022-04-20
EP2527007B1 (en) 2016-03-30
US20170267693A1 (en) 2017-09-21
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
DK3284520T3 (da) 2019-09-16
LTPA2021512I1 (el) 2021-07-12
US20150232479A1 (en) 2015-08-20
LU92446I2 (fr) 2015-10-29
EP3372281B1 (en) 2021-07-07
US9051337B2 (en) 2015-06-09
IL215788A0 (en) 2011-12-29
WO2006116764A1 (en) 2006-11-02
HUS1400039I1 (hu) 2016-08-29
PT3284520T (pt) 2019-09-10
US20170224694A1 (en) 2017-08-10
SI2465580T1 (sl) 2014-04-30
SI1874117T1 (sl) 2014-01-31
US20170260203A1 (en) 2017-09-14
IL225206A (en) 2017-11-30
MX2007013351A (es) 2008-01-21
NL301109I2 (nl) 2021-09-15

Similar Documents

Publication Publication Date Title
CY2021016I2 (el) Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
CY2022037I2 (el) Ιμιδαζοτριαζινες με ιμιδαζοπυριμιδινες ως αναστολεις κινασης
DK1948666T3 (da) HIV-intergrasehæmmere
ATE503403T1 (de) Möbel
ATE487691T1 (de) Acetylenderivate
DE602006021542D1 (de) Resolver-anordnung
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
FI20055648L (fi) Jauhinterä
DE112005003670A5 (de) Eventanordnung
ATE541837T1 (de) Oxaphenanthren-derivate
DE602006011251D1 (de) Druckmaschinenanordnung
FR2884835B1 (fr) Tricot demaillable
DE602006019209D1 (de) Fluoroalkylpyrrolidin-derivate
FI6884U1 (fi) Trukin lisälaite
FI6744U1 (fi) Hyllyjärjestelmä
ES1059473Y (es) Estanteria
ITVI20050213A1 (it) Scaffalatura
FI20055337L (fi) Kuormalava
FI20051158A0 (fi) Kuormalava
FI7461U1 (fi) Järjestely kuormalavassa
FIU20050149U0 (fi) Puerta metalica con panel embellecedor incorporado
ATE485274T1 (de) Phenylpyridonderivat